Sonoma Pharmaceuticals (SNOA) Competitors $3.54 -0.26 (-6.84%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$3.53 -0.01 (-0.31%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. GRCE, CASI, EGRX, OVID, LGVN, CALC, TENX, CARA, CYTH, and JATTShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Grace Therapeutics (GRCE), CASI Pharmaceuticals (CASI), Eagle Pharmaceuticals (EGRX), Ovid Therapeutics (OVID), Longeveron (LGVN), CalciMedica (CALC), Tenax Therapeutics (TENX), Cara Therapeutics (CARA), Cyclo Therapeutics (CYTH), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Grace Therapeutics CASI Pharmaceuticals Eagle Pharmaceuticals Ovid Therapeutics Longeveron CalciMedica Tenax Therapeutics Cara Therapeutics Cyclo Therapeutics JATT Acquisition Grace Therapeutics (NASDAQ:GRCE) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, community ranking, media sentiment and valuation. Which has stronger earnings & valuation, GRCE or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$12.85M-$1.16-2.34Sonoma Pharmaceuticals$13.97M0.41-$4.84M-$4.02-0.88 Is GRCE or SNOA more profitable? Grace Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -26.82%. Grace Therapeutics' return on equity of -20.10% beat Sonoma Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -20.10% -17.10% Sonoma Pharmaceuticals -26.82%-68.98%-26.39% Which has more volatility and risk, GRCE or SNOA? Grace Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Do analysts rate GRCE or SNOA? Grace Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 342.80%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Grace Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor GRCE or SNOA? In the previous week, Grace Therapeutics and Grace Therapeutics both had 1 articles in the media. Grace Therapeutics' average media sentiment score of 1.91 beat Sonoma Pharmaceuticals' score of 1.89 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Grace Therapeutics Very Positive Sonoma Pharmaceuticals Very Positive Does the MarketBeat Community believe in GRCE or SNOA? Sonoma Pharmaceuticals received 215 more outperform votes than Grace Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Grace Therapeutics an outperform vote while only 67.50% of users gave Sonoma Pharmaceuticals an outperform vote. CompanyUnderperformOutperformGrace TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesSonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Do institutionals and insiders hold more shares of GRCE or SNOA? 6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryGrace Therapeutics beats Sonoma Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.72M$4.33B$5.53B$7.93BDividend YieldN/A39.93%5.11%4.22%P/E Ratio-0.8830.0322.5118.54Price / Sales0.4155.31397.62103.30Price / CashN/A51.0838.1834.62Price / Book1.186.056.734.25Net Income-$4.84M$68.71M$3.22B$248.18M7 Day Performance-16.31%-0.24%1.38%1.03%1 Month Performance63.89%-2.90%2.79%2.70%1 Year Performance2,212.21%21.00%15.41%4.05% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals1.0138 of 5 stars$3.54-6.8%N/A+2,210.7%$5.72M$13.97M-0.88180Positive NewsGRCEGrace Therapeutics2.3855 of 5 stars$2.51+0.8%$12.00+378.1%N/A$25.45MN/A-2.16N/APositive NewsGap DownCASICASI Pharmaceuticals3.8438 of 5 stars$2.03-1.0%$4.00+97.0%-14.9%$24.97M$28.54M-0.91180EGRXEagle PharmaceuticalsN/A$1.92+12.9%N/A-53.2%$24.94M$257.55M0.00100Analyst ForecastGap DownOVIDOvid Therapeutics4.4513 of 5 stars$0.35+0.9%$3.03+766.7%-89.7%$24.88M$566,000.00-0.7460Gap UpLGVNLongeveron2.5436 of 5 stars$1.65-5.7%$8.67+425.3%-10.3%$24.63M$2.39M-0.2620Positive NewsGap UpCALCCalciMedica2.2856 of 5 stars$1.51+0.7%$18.00+1,092.1%-74.3%$24.54MN/A-1.4030TENXTenax Therapeutics2.55 of 5 stars$5.87+1.2%$18.00+206.6%+46.9%$24.35MN/A-1.109Analyst ForecastPositive NewsCARACara Therapeutics3.8723 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Analyst ForecastPositive NewsGap DownHigh Trading VolumeCYTHCyclo Therapeutics1.3613 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809JATTJATT AcquisitionN/A$1.37-4.9%N/A-62.9%$23.63MN/A0.003High Trading Volume Related Companies and Tools Related Companies Grace Therapeutics Competitors CASI Pharmaceuticals Competitors Eagle Pharmaceuticals Competitors Ovid Therapeutics Competitors Longeveron Competitors CalciMedica Competitors Tenax Therapeutics Competitors Cara Therapeutics Competitors Cyclo Therapeutics Competitors JATT Acquisition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNOA Stock Free SNOA Stock Alerts